Syed Haider

14.6k total citations · 3 hit papers
111 papers, 5.0k citations indexed

About

Syed Haider is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Syed Haider has authored 111 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Molecular Biology, 49 papers in Cancer Research and 29 papers in Oncology. Recurrent topics in Syed Haider's work include Cancer Genomics and Diagnostics (23 papers), Cancer, Hypoxia, and Metabolism (17 papers) and Epigenetics and DNA Methylation (15 papers). Syed Haider is often cited by papers focused on Cancer Genomics and Diagnostics (23 papers), Cancer, Hypoxia, and Metabolism (17 papers) and Epigenetics and DNA Methylation (15 papers). Syed Haider collaborates with scholars based in United Kingdom, Canada and United States. Syed Haider's co-authors include Arek Kasprzyk, Damian Smedley, Benoît Ballester, Adrian L. Harris, Paul C. Boutros, Richard Holland, Darin London, Guðmundur Á. Þórisson, Francesca M. Buffa and Peter Rice and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Syed Haider

102 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

BioMart – biological queries made easy

2009 639 citations Syed Haider, Arek Kasprzyk et al. profile →
Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival

2014 261 citations Hani Choudhry, Matteo Morotti et al. profile →
Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade

2022 151 citations Liam Jenkins, Ute Jungwirth et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Syed Haider United Kingdom	36	3.3k	1.6k	1.0k	602	597	111	5.0k
Joshua F. McMichael United States	11	3.3k 1.0×	2.0k 1.3×	1.5k 1.4×	616 1.0×	789 1.3×	16	5.8k
Song Liu United States	41	2.9k 0.9×	1.4k 0.9×	1.3k 1.2×	525 0.9×	478 0.8×	167	4.9k
Crispin Miller United Kingdom	38	3.7k 1.1×	1.8k 1.1×	1.1k 1.1×	365 0.6×	589 1.0×	94	5.4k
E. Aubrey Thompson United States	42	3.3k 1.0×	1.2k 0.8×	1.6k 1.5×	404 0.7×	486 0.8×	112	5.0k
Richard Bourgon United States	28	3.5k 1.0×	1.1k 0.7×	1.4k 1.3×	549 0.9×	477 0.8×	55	5.4k
Hannah Carter United States	31	2.6k 0.8×	1.3k 0.8×	945 0.9×	880 1.5×	393 0.7×	95	4.4k
Trevor J. Pugh Canada	34	2.8k 0.8×	1.3k 0.8×	1.4k 1.3×	602 1.0×	700 1.2×	149	5.0k
Johan Vallon‐Christersson Sweden	35	2.9k 0.9×	2.0k 1.3×	1.4k 1.4×	953 1.6×	524 0.9×	90	4.8k
Nigel P. Mongan United Kingdom	39	3.7k 1.1×	1.3k 0.9×	1.1k 1.0×	627 1.0×	800 1.3×	158	5.7k
Jacqui Shaw United Kingdom	39	2.5k 0.8×	2.1k 1.4×	1.6k 1.6×	546 0.9×	754 1.3×	124	5.1k

Countries citing papers authored by Syed Haider

Since Specialization

Citations

This map shows the geographic impact of Syed Haider's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Syed Haider with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Syed Haider more than expected).

Fields of papers citing papers by Syed Haider

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Syed Haider. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Syed Haider. The network helps show where Syed Haider may publish in the future.

Co-authorship network of co-authors of Syed Haider

This figure shows the co-authorship network connecting the top 25 collaborators of Syed Haider. A scholar is included among the top collaborators of Syed Haider based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Syed Haider. Syed Haider is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khan, Omar, Muhammad Alvi, Marina Salluzzi, et al.. (2025). 116P: Predicting overall survival (OS) differences and treatment duration from longitudinal ai-driven imaging-based prognostication (IPRO) and first-line (1L) treatment status among patients with advanced non-small cell lung cancer (aNSCLC). Journal of Thoracic Oncology. 20(3). S83–S83.

Zhang, Yu, Ioanna Mavrommati, Chris Starling, et al.. (2024). Abstract PO4-13-11: Epigenetically defined sub-clonal heterogeneity drives therapy resistance in triple-negative breast cancer. Cancer Research. 84(9_Supplement). PO4–13. 1 indexed citations

Cutts, Ros, Sarah Hrebien, Aditi Gulati, et al.. (2024). Discriminating subtypes in advanced breast cancer with ctDNA methylation profiling.. Journal of Clinical Oncology. 42(16_suppl). 1013–1013.

Fitzpatrick, Amanda, Marjan Iravani, David Vicente, et al.. (2023). Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype. Nature Communications. 14(1). 7408–7408. 9 indexed citations

Tovey, Holly, Joel S. Parker, Katherine A. Hoadley, et al.. (2023). Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727). Clinical Cancer Research. 29(18). 3691–3705. 3 indexed citations

Iravani, Marjan, Rania El Botty, John Alexander, et al.. (2023). Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers. Cancer Research. 84(1). 17–25. 6 indexed citations

Jenkins, Liam, Ute Jungwirth, Alexandra Avgustinova, et al.. (2022). Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade. Cancer Research. 82(16). 2904–2917. 151 indexed citations breakdown →

Jungwirth, Ute, Antoinette van Weverwijk, Liam Jenkins, et al.. (2021). Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis. Nature Communications. 12(1). 3516–3516. 43 indexed citations

Fitzpatrick, Amanda, Marjan Iravani, Lucy Childs, et al.. (2021). Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis. Clinical Cancer Research. 28(6). 1180–1191. 44 indexed citations

10.

Holgersen, Erle M., Andrea Gillespie, Olivia C. Leavy, et al.. (2021). Identifying high-confidence capture Hi-C interactions using CHiCANE. Nature Protocols. 16(4). 2257–2285. 11 indexed citations

11.

Pettitt, Stephen J., Jessica Frankum, Marco Punta, et al.. (2020). Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance. Cancer Discovery. 10(10). 1475–1488. 114 indexed citations

12.

Bergerhoff, Katharina, Shane Foo, Emmanuel C. Patin, et al.. (2020). Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer. Journal for ImmunoTherapy of Cancer. 8(2). e000698–e000698. 24 indexed citations

13.

Morotti, Matteo, Esther Bridges, Alessandro Valli, et al.. (2019). Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. Proceedings of the National Academy of Sciences. 116(25). 12452–12461. 105 indexed citations

14.

Jones, Dylan T., Alessandro Valli, Syed Haider, et al.. (2018). 3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers. Molecular Cancer Therapeutics. 18(2). 376–388. 20 indexed citations

15.

Li, Constance H., Syed Haider, Yu-Jia Shiah, Kevin Thai, & Paul C. Boutros. (2018). Sex Differences in Cancer Driver Genes and Biomarkers. Cancer Research. 78(19). 5527–5537. 105 indexed citations

16.

Naidoo, Kuban D., Patty T. Wai, Sarah Maguire, et al.. (2018). Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer. Molecular Cancer Therapeutics. 17(1). 306–315. 54 indexed citations

17.

Leavy, Olivia C., Nicola H. Dryden, Sarah Maguire, et al.. (2018). Capture Hi-C identifies putative target genes at 33 breast cancer risk loci. Nature Communications. 9(1). 1028–1028. 72 indexed citations

18.

Starmans, Maud H. W., Melania Pintilie, Michelle Chan‐Seng‐Yue, et al.. (2015). Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung. Clinical Cancer Research. 21(6). 1477–1486. 10 indexed citations

19.

Barth, Rolf F., George W. Kabalka, Weilian Yang, et al.. (2013). Evaluation of unnatural cyclic amino acids as boron delivery agents for treatment of melanomas and gliomas. Applied Radiation and Isotopes. 88. 38–42. 20 indexed citations

20.

Movassagh, Mehregan, Mun‐Kit Choy, David A. Knowles, et al.. (2011). Distinct Epigenomic Features in End-Stage Failing Human Hearts. Circulation. 124(22). 2411–2422. 217 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact